Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ATOSSA THERAPEUTICS, INC. Director's Dealing 2018

Jun 29, 2018

34113_dirs_2018-06-29_b085101d-0c97-4406-bbb0-367bf115c718.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ATOSSA GENETICS INC (ATOS)
CIK: 0001488039
Period of Report: 2018-06-27

Reporting Person: Remmel H. Lawrence (Director)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2018-06-27 Stock Option (right to buy) $2.38 A 45000 Acquired 2028-06-27 Common Stock (45000) Direct

Footnotes

F1: The options shall vest on a quarterly basis over the next 12 months.